Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators

Javed Butler,Gregg C Fonarow,Christopher O'Connor,Kirkwood Adams,Robert O Bonow,Robert J Cody,Sean P Collins,Preston Dunnmon,Wilfried Dinh,Mona Fiuzat,Vasiliki V Georgiopoulou,Stephen Grant,So-Young Kim,Stuart Kupfer,Martin Lefkowitz,Robert J Mentz,Frank Misselwitz,Bertram Pitt,Lothar Roessig,Erik Schelbert,Monica Shah,Scott Solomon,Norman Stockbridge,Clyde Yancy,Mihai Gheorghiade
DOI: https://doi.org/10.1016/j.ahj.2014.12.001
Abstract:Advances in medical therapies leading to improved patient outcomes are in large part related to successful conduct of clinical trials that offer critical information regarding the efficacy and safety of novel interventions. The conduct of clinical trials in the United States, however, continues to face increasing challenges with recruitment and retention. These trends are paralleled by an increasing shift toward more multinational trials where most participants are enrolled in countries outside the United States, bringing into question the generalizability of the results to the American population. This manuscript presents the perspectives and recommendations from clinicians, researchers, sponsors, and regulators who attended a meeting facilitated by the Food and Drug Administration to improve upon the current clinical trial trends in the United States.
What problem does this paper attempt to address?